Clinical experience with ceraxon used in ischemic stroke
Abstract
Citicoline (Ceraxon) is a neuroprotective agent used in acute ischemic stroke (IS) and chronic cerebrovascular diseases. The efficiency and safety of Ceraxon intravenously in a dose of2000 mg/day for 10 days, then orally for 35 days with evaluation of its effect on cognitive functions were studied in 24 patients (13 men, 11 women; mean age 68.2+9.3 years) with IS. During treatment, none of the patients died or developed recurrent stroke, myocardial infarction, or other vascular events. A gradual regression of neurological disorders and a lower degree of disability were observed in most patients (18/24). Ceraxon was found to have a positive effect on cognitive function and their improvement on day 45 after disease onset. The findings agree with the results of the multicenter studies showing the efficacy and safety of citicoline in IS.
About the Authors
V. A. Parfenov
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
T. G. Fateyeva
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
O. V. Kosivtsova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. <div><p>Дамулин И.В., Парфенов В.А., Скоромец А.А. и др. Нарушения кровообращения в головном и спинном мозге. В кн.: Болезни нервной системы. Рук-во для врачей. Т. 1. Под ред. Н.Н. Яхно. М.: Медицина, 2005;с. 232-303.</p><p>Инсульт: диагностика, лечение и профилактика. Под ред. З.А. Суслиной, М.А. Пирадова. М.: МЕДпресс-информ, 2008;288 с.</p><p>Adams H.P., del Zoppo Jr.G., Alberts M.J. Guidelines for the Early Management of Adults With bcriemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and !ntervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-711.</p><p>European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis 2008;25:457-507.</p><p>Lozano Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittelforschung 1983;33:1073-80.</p><p>Aronowski J., Strong R., Grotta J.C. Citicoline for treatment of experimental focal ischemia: histologic and behavioral outcome. Neurol Res 1996;18:570-4.</p><p>Conant R., Schauss A.G. Therapeutic Applications of Citicoline for Stroke and Cognitive Dysfunction in the Elderly: A Review of the Literature. Altern Med Rev 2004;9:17-31.</p><p>Hurtado O., Gardenas A., Pradillo J.M. et al. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol Dis 2007;26:105-11.</p><p>Schabitz W.R., Weber J., Takano K. et al. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci 1996;138:21-5.</p><p>Clark W.M., Warach S.J., Pettigrew L.C. et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 1997;49:671-8.</p><p>Clark W.M., Williams B.J., Selzer K.A. et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999;30:2592-7.</p><p>Clark W.M., Wechsler L.R., Sabounjian L.A., Schwiderski U.E.; Citicoline Stroke Study Group. A phase ІІІ randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001;57:1595-602.</p><p>Dаvalos A., Castillo J., Alvarez-Sabin J. et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 2002;33:2850-7.</p><p>Cho H.J., Kim Y.J. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol 2009;31:171-6.</p><p>Alvarez X.A., Laredo M., Corzo D. et al. Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol 1997;19:201-10.</p><p>Fioravanti M., Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005 Apr 18;(2):CD000269.</p><p>Alonso de Lecinana M., Gutierrez M., Roda J.M. et al. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. J Neurol Sci 2006;247:121-9.</p><p>Andersen M., Overgaard K., Meden P. et al. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 1999;30:1464-71.</p><p>Bolland K., Whitehead J., Cobo E. et al. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. Pharm Stat 2009;8:136-49.</p></div><br />
Review
For citations:
Parfenov V.A., Fateyeva T.G., Kosivtsova O.V. Clinical experience with ceraxon used in ischemic stroke. Neurology, Neuropsychiatry, Psychosomatics. 2010;2(3):67-70. (In Russ.) https://doi.org/10.14412/2074-2711-2010-104
Views: 1243
Email this article 